Evaluation of the warfarin-resistance polymorphism, VKORC1 Asp36Tyr, and its effect on dosage algorithms in a genetically heterogeneous anticoagulant clinic

Kamali, 2010, Pharmacogenetics of warfarin, Annu Rev Med, 61, 63, 10.1146/annurev.med.070808.170037 Li, 2004, Identification of the gene for vitamin K epoxide reductase, Nature, 427, 541, 10.1038/nature02254 Rost, 2004, Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2, Nature, 427, 537, 10.1038/nature02214 Wajih, 2004, The inhibitory effect of calumenin on the vitamin K-dependent gamma-carboxylation system. Characterization of the system in normal and warfarin-resistant rats, J Biol Chem, 279, 25276, 10.1074/jbc.M401645200 Cain, 1997, Assembly of the warfarin-sensitive vitamin K 2,3-epoxide reductase enzyme complex in the endoplasmic reticulum membrane, J Biol Chem, 272, 29068, 10.1074/jbc.272.46.29068 Wadelius, 2005, Common VKORC1 and GGCX polymorphisms associated with warfarin dose, Pharmacogenomics J, 5, 262, 10.1038/sj.tpj.6500313 Wadelius, 2007, Association of warfarin dose with genes involved in its action and metabolism, Hum Genet, 121, 23, 10.1007/s00439-006-0260-8 Pautas, 2010, Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients, Clin Pharmacol Ther, 87, 57, 10.1038/clpt.2009.178 Rieder, 2005, Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose, N Engl J Med, 352, 2285, 10.1056/NEJMoa044503 Carlquist, 2010, An evaluation of nine genetic variants related to metabolism and mechanism of action of warfarin as applied to stable dose prediction, J Thromb Thrombolysis, 30, 358, 10.1007/s11239-010-0467-3 Ciccacci, 2011, EPHX1 polymorphisms are not associated with warfarin response in an Italian population, Clin Pharmacol Ther, 89, 791, 10.1038/clpt.2011.31 Moridani, 2006, Frequency of CYP2C9 polymorphisms affecting warfarin metabolism in a large anticoagulant clinic cohort, Clin Biochem, 39, 606, 10.1016/j.clinbiochem.2006.01.023 Sconce, 2005, The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen, Blood, 106, 2329, 10.1182/blood-2005-03-1108 Gage, 2008, Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin, Clin Pharmacol Ther, 84, 326, 10.1038/clpt.2008.10 Wadelius, 2009, The largest prospective warfarin-treated cohort supports genetic forecasting, Blood, 113, 784, 10.1182/blood-2008-04-149070 International Warfarin Pharmacogenetics Consortium, 2009, Estimation of the warfarin dose with clinical and pharmacogenetic data, N Engl J Med, 360, 753, 10.1056/NEJMoa0809329 You, 2010, Warfarin dosing algorithm using clinical, demographic and pharmacogenetic data from Chinese patients, J Thromb Thrombolysis, 31, 113, 10.1007/s11239-010-0497-x Schelleman, 2008, Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans, Clin Pharmacol Ther, 84, 332, 10.1038/clpt.2008.101 Ross, 2010, Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements, J Hum Genet, 55, 582, 10.1038/jhg.2010.73 Limdi, 2010, Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups, Blood, 115, 3827, 10.1182/blood-2009-12-255992 Rubin, 1999, Determinants of peak bone mass: clinical and genetic analyses in a young female Canadian cohort, J Bone Miner Res, 14, 633, 10.1359/jbmr.1999.14.4.633 Scott, 2008, Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations, Am J Hum Genet, 82, 495, 10.1016/j.ajhg.2007.10.002 Bodin, 2008, Multiple genetic alterations in vitamin K epoxide reductase complex subunit 1 gene (VKORC1) can explain the high dose requirement during oral anticoagulation in humans, J Thromb Haemost, 6, 1436, 10.1111/j.1538-7836.2008.03049.x Aklillu, 2008, VKORC1 Asp36Tyr warfarin resistance marker is common in Ethiopian individuals, Blood, 111, 3903, 10.1182/blood-2008-01-135863 Loebstein, 2007, A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance, Blood, 109, 2477, 10.1182/blood-2006-08-038984 Watzka, 2011, Thirteen novel VKORC1 mutations associated with oral anticoagulant resistance: insights into improved patient diagnosis and treatment, J Thromb Haemost, 9, 109, 10.1111/j.1538-7836.2010.04095.x